Choroba wieńcowa u chorych z POChP Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Piotr Sobieraj
Krzysztof Dęmbe
Przemysław Krasnodębski
Beata Mrozikiewicz-Rakowska
Janusz Krzymień

Abstrakt

Przewlekła choroba obturacyjna płuc (POChP) jest chorobą, która występuje coraz częściej. Według szacunkowych danych POChP w krótkim czasie stanie się trzecią pod względem częstości przyczyną zgonów na świecie. Choroba wieńcowa jest prawdopodobnie najczęstszą i najpoważniejszą chorobą u chorych z POChP. Na występowanie i przebieg choroby wieńcowej w tej grupie wpływa częstsze występowanie tradycyjnych czynników ryzyka choroby wieńcowej, systemowe zapalenie, narażenie na hipoksję, aktywacja układu współczulnego, uszkodzenie naczyń oraz przyspieszenie procesu starzenia. Podobieństwo objawów, potencjalne trudności w wykonaniu testów wysiłkowych oraz przeciwwskazania do stosowania leków używanych podczas wysiłkowych testów farmakologicznych sprawiają, że diagnostyka choroby wieńcowej u chorych z POChP wymaga szczególnego zaangażowania i czujności lekarza. Wytyczne GOLD i ESC nie opisują w sposób szczegółowy optymalnych metod leczenia pacjentów z POChP i chorobą wieńcową. Niniejszy artykuł przedstawia dane dotyczące epidemiologii i etiologii choroby wieńcowej u pacjentów z POChP oraz wpływu leków i innych metod leczenia typowo stosowanych w chorobie wieńcowej i POChP.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Sobieraj , P., Dęmbe , K., Krasnodębski , P., Mrozikiewicz-Rakowska , B., & Krzymień , J. (2015). Choroba wieńcowa u chorych z POChP . Kardiologia W Praktyce, 9(3), 31-38. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1336
Dział
Artykuły

Bibliografia

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Online: http://www.goldcopd.org/.
2. Niepsuj G., Kozielski J., Niepsuj K. et al.: Przewlekła obturacyjna choroba płuc wśród mieszkańców Zabrza. Wiad. Lek. 2002; 55(supl. 1): 354-359.
3. Enriquez J.R., de Lemos J.A., Parikh S.V. et al.: Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. Am. Heart J. 2013; 165: 43.
4. Mapel D.W., Dedrick D., Davis K.: Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005; 2(1): 35-41.
5. Feary J., Rodrigues L., Smith C. et al.: Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 95.
6. Calverley P.M., Anderson J.A., Celli B. et al.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775.
7. Anthonisen N.R., Connett J.E., Kiley J.P. et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497-1505.
8. Sidney S., Sorel M., Quesenberry C.P. Jr et al.: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
9. Sin D.D., Man S.F.: Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8.
10. Reed R.M., Eberlein M., Girgis R.E. et al.: Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am. J. Med. 2012; 125: 1228.
11. Mannino D.M., Thorn D., Swensen A. et al.: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Eur. Respir. J. 2008; 32: 962-969.
12. Donaldson G.C., Hurst J.R., Smith C.J. et al.: Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091.
13. Di Marco F., Verga M., Reggente M. et al.: Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir. Med. 2006; 100: 1767-1774.
14. Sin D.D., Man J.P., Man S.F.: The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am. J. Med. 2003; 114: 10-14.
15. Ernst P., Baltzan M., Deschenes J. et al.: Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur. Respir. J. 2006; 27: 1168-1174.
16. Shih H.T., Webb C.R., Conway W.A. et al.: Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94(1): 44-48.
17. Basili S., Ferroni P., Vieri M., et al.: Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis 1999; 147(2): 249-252.
18. Gan W.Q., Man S.F.P., Senthilselvan A. et al.: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59(7): 574-580.
19. de Torres J.P., Cordoba-Lanus E., López-Aguilar C. et al.: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006; 27(5): 902-907.
20. Dahl M., Vestbo J., Lange P. et al.: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175(3): 250-255.
21. Lattimore J.-D.L., Wilcox I., Nakhla S. et al.: Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis 2005; 179(2): 255-259.
22. Ichikawa H., Flores S., Kvietys P.R. et al.: Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ. Res. 1997; 81(6): 922-931.
23. Hartmann G., Tschöp M., Fischer R. et al.: High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 2000; 12(3): 246-252.
24. Savransky V., Nanayakkara A., Li J. et al.: Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007; 175(12): 1290-1297.
25. Cook S., Togni M., Schaub M.C. et al.: Hess OM High heart rate: a cardiovascular risk factor? Eur. Heart. J. 2006; 27(20): 2387-2393.
26. Volterrani M., Scalvini S., Mazzuero G. et al.: Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest 1994; 106(5): 1432-1437.
27. Iwamoto H., Yokoyama A., Kitahara Y. et al.: Airfl ow limitation in smokers is associated with subclinical atherosclerosis. Am. J. Respir. Crit. Care Med. 2009; 179(1): 35-40.
28. van Gestel Y.R.B.M., Flu W.J., van Kuijk J.P. et al.: Association of COPD with carotid wall intima-media thickness in vascular surgery patients. Respir. Med. 2010; 104(5): 712-716.
29. Barr R.G., Mesia-Vela S., Austin J.H. et al.: Impaired flowmediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am. J. Respir. Crit. Care Med. 2007; 176(12): 1200-1207.
30. Eickhoff P., Valipour A., Kiss D. et al.: Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 178(12): 1211-1218.
31. Sabit R., Bolton C.E., Edwards P.H. et al.: Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175(12): 1259-1265.
32. Coulson J.M., Rudd J.H., Duckers J.M. et al.: Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18 F-FDG PET pilot study. J. Nucl. Med. 2010; 51(9): 1357-1360.
33. Savale L., Chaouat A., Bastuji-Garin S. et al.: Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 179(7): 566-571.
34. Tsuji T., Aoshiba K., Nagai A.: Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2006; 174(8): 886-893.
35. Minamino T., Miyauchi H., Yoshida T. et al.: Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105(13): 1541-1544.
36. Bürrig K.F.: The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler. Thromb. 1991; 11(6): 1678-1689.
37. Abroug F., Ouanes-Besbes L., Nciri N. et al.: Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am. J. Respir. Crit. Care Med. 2006; 174: 990.
38. McAllister D.A., Maclay J.D., Mills N.L. et al.: Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur. Respir J. 2012; 39: 1097.
39. Søyseth V., Bhatnagar R., Holmedahl N.H. et al.: Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99: 122.
40. Brekke P.H., Omland T., Smith P. et al.: Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine 2008; 102: 1243-1247.
41. Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia Przewlekłej Obturacyjnej Choroby Płuc. Pneumonologia i Alergologia Polska 2014; 3(82): 227-263.
42. 2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal 2013; 34: 2949-3003.
43. Reid W.D., Yamabayashi C., Goodridge D. et al.: Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 297.
44. Celli B., Decramer M., Kesten S. et al.: Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 948.
45. Celli B., Decramer M., Leimer I. et al.: Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137: 20.
46. Hilleman D.E., Malesker M.A., Morrow L.E. et al.: A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 253.
47. Suissa S., Assimes T., Ernst P.: Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58: 43.
48. Ferguson G.T., Funck-Brentano C., Fischer T. et al.: Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817.
49. Calverley P.M., Anderson J.A., Celli B. et al.: Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719.
50. White W.B., Cooke G.E., Kowey P.R. et al.: Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013; 144: 758.
51. Oba Y., Lone N.A.: Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther. Adv. Respir. Dis. 2013; 7: 13.
52. Foresi A., Cavigioli G., Signorelli G. et al.: Is the use of β-blockers in COPD still an unresolved dilemma? Respiration 2010; 80: 177.
53. Rutten F.H., Zuithoff N.P., Hak E. et al.: Β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2010; 170: 880.
54. Au D.H., Bryson C.L., Fan V.S. et al.: Β-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am. J. Med. 2004; 117: 925.
55. Benson M.K., Berrill W.T., Cruickshank J.M. et al.: A comparison of four β-adrenoceptor antagonists in patients with asthma. Br. J. Clin. Pharmacol. 1978; 5: 415.
56. Fogari R., Zoppi A., Tettamanti F. et al.: Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc. Drugs. Ther. 1990; 4: 1145.
57. Chazan R.: Atenolol in the treatment of patients with airway obstruction. Pol. Merkur. Lek. 1998; 4: 89.
58. Salpeter S., Ormiston T., Salpeter E.: Cardioselective β-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2005; CD003566.
59. Salpeter S.R., Ormiston T.M., Salpeter E.E. et al.: Cardioselective β-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir. Med. 2003; 97: 1094.
60. Salpeter S.R., Ormiston T.M., Salpeter E.E.: Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann. Intern. Med. 2002; 137: 715.
61. van Gestel Y.R., Hoeks S.E., Sin D.D. et al.: Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am. J. Respir. Crit. Care Med. 2008; 178: 695.
62. Dransfield M.T., Rowe S.M., Johnson J.E. et al.: Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301.
63. Saleh H.Z., Mohan K., Shaw M. et al.: Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing non-emergent coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 2012; 42: 108.
64. Samuels L.E., Kaufman M.S., Morris R.J. et al.: Coronary artery bypass grafting in patients with COPD. Chest 1998; 113: 878.
65. Michalopoulos A., Geroulanos S., Papadimitriou L. et al.: Mild or moderate chronic obstructive pulmonary disease risk in elective coronary artery bypass grafting surgery. World J. Surg. 2001; 25: 1507.
66. Fuster R.G., Argudo J.A., Albarova O.G. et al.: Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 2006; 29: 202.
67. Enriquez J.R., Parikh S.V., Selzer F. et al.: Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011; 140: 604.